Procept BioRobotics' (PRCT) estimate of its addressable market "is overly exaggerated," Spruce Point Capital Management said in a short report Thursday.
Spruce Point also said the company's claim that it will fundamentally change current benign prostatic hyperplasia protocols is "unrealistic, since there is no one-size-fits-all BPH treatment."
Procept BioRobotics didn't immediately respond to a request for comment from MT Newswires.
The company's shares were down 0.9% in recent trading.
Price: 77.64, Change: -0.67, Percent Change: -0.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.